| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 14.23M | 19.83M | 27.88M | 19.25M | 39.33M | 27.88M |
| Gross Profit | -5.73M | -2.99M | 7.83M | -7.18M | -6.77M | -342.89K |
| EBITDA | -7.89M | -6.13M | 5.04M | -9.06M | -11.87M | -4.08M |
| Net Income | -8.99M | -6.55M | 4.77M | -10.02M | -10.89M | -3.21M |
Balance Sheet | ||||||
| Total Assets | 50.62M | 48.30M | 28.05M | 17.92M | 24.10M | 28.77M |
| Cash, Cash Equivalents and Short-Term Investments | 4.85M | 10.66M | 8.84M | 1.00M | 3.12M | 13.07M |
| Total Debt | 38.45M | 31.31M | 9.07M | 7.62M | 2.63M | 2.78M |
| Total Liabilities | 46.75M | 40.45M | 19.28M | 15.75M | 12.21M | 12.50M |
| Stockholders Equity | 3.88M | 7.85M | 8.77M | 2.17M | 11.88M | 16.27M |
Cash Flow | ||||||
| Free Cash Flow | -26.62M | -21.50M | 6.89M | -6.80M | -15.21M | -2.59M |
| Operating Cash Flow | -3.24M | -5.66M | 7.24M | -5.36M | -11.77M | 156.59K |
| Investing Cash Flow | -21.51M | -15.08M | -3.92M | -1.44M | -3.44M | -4.49M |
| Financing Cash Flow | 16.22M | 23.33M | 915.22K | 4.68M | 5.26M | 14.49M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
66 Neutral | $17.65B | 18.10 | 5.60% | 3.62% | 6.62% | 11.55% | |
55 Neutral | AU$25.36M | 36.90 | 14.11% | ― | -11.85% | 6.25% | |
50 Neutral | AU$18.26M | -4.90 | -38.32% | ― | 2.69% | -273.87% | |
44 Neutral | AU$22.43M | -7.86 | -11.34% | ― | -8.52% | 13.51% | |
44 Neutral | AU$8.32M | -1.06 | -47.12% | ― | ― | -15.24% | |
43 Neutral | AU$21.59M | -1.89 | -129.44% | ― | -29.97% | -284.16% | |
34 Underperform | AU$13.46M | 0.05 | -84.32% | ― | ― | 91.54% |
Delorean Corporation has issued an investor update dated late February 2026 outlining general information about its business and operations in the bioenergy sector. The document emphasises that the material is a high-level overview and may change without notice, and that investors should undertake their own assessment rather than rely solely on the presentation.
The update underscores that any securities in Delorean are speculative, and it does not constitute an offer or recommendation to buy or sell shares in any jurisdiction, including the United States. It also stresses that the company and its advisers disclaim liability for inaccuracies or omissions, and that forward-looking commentary is inherently uncertain and subject to significant risks and assumptions.
Delorean further notes that its securities are not registered under U.S. securities law and may only be offered in compliance with applicable exemptions. The company reiterates that the presentation is not financial advice, has not taken individual circumstances into account, and that recipients must make independent inquiries into the risks and suitability of any investment in Delorean.
The most recent analyst rating on (AU:DEL) stock is a Hold with a A$0.11 price target. To see the full list of analyst forecasts on Delorean Corporation Ltd stock, see the AU:DEL Stock Forecast page.
Delorean Corporation has released its interim financial report for the half-year ended 31 December 2025, outlining its progress toward becoming a leading renewable energy generator and retailer in Australia and New Zealand. The update highlights its growing bioenergy infrastructure footprint, including initiatives such as the YVW Food Waste to Energy Project, underscoring the company’s strategic focus on converting waste streams into renewable energy and reinforcing its position in the expanding bioenergy market.
The most recent analyst rating on (AU:DEL) stock is a Hold with a A$0.11 price target. To see the full list of analyst forecasts on Delorean Corporation Ltd stock, see the AU:DEL Stock Forecast page.
Delorean Corporation ended the December 2025 quarter with a cash balance of $4.8 million and customer receipts of $1.8 million, while materially progressing its core bioenergy project pipeline. The company achieved practical completion of Yarra Valley Water’s $53 million Lilydale food-waste-to-energy facility and moved into an $8 million operations and maintenance phase, advanced construction of its flagship SA1 Salisbury Build-Own-Operate asset in Adelaide and secured the first $2.7 million milestone payment from ARENA, and continued to lock in long-term feedstock agreements. While Brickworks chose not to proceed to a final investment decision on the proposed NSW1 Horsley Park bioenergy plant, Delorean is pursuing alternative pathways to bring a New South Wales project to construction, continued development work on its VIC1 project toward an expected final investment decision in the second half of FY26, and signed a strategic MOU and master services agreement with Opal for an Opal-funded feasibility study at the Maryvale paper mill that could lead to further bioenergy developments nationally under its BOO model. These operational milestones and policy tailwinds — including the launch of the NSW Renewable Fuel Scheme and Renewable Fuels Strategy, which elevate renewable gas as a key decarbonisation tool — strengthen Delorean’s positioning in Australia’s emerging renewable gas market and support the long-term economics of its project pipeline for investors and stakeholders.
The most recent analyst rating on (AU:DEL) stock is a Sell with a A$0.08 price target. To see the full list of analyst forecasts on Delorean Corporation Ltd stock, see the AU:DEL Stock Forecast page.
Delorean Corporation has confirmed that its proposed Horsley Park Bioenergy plant in New South Wales will not proceed after partner Brickworks chose not to move toward a final investment decision on the jointly developed project. In response, Delorean plans to redirect its efforts to other project opportunities in NSW, advance its VIC1 project into construction, and continue progressing construction of its wholly owned SA1 facility, signalling a reallocation of capital and management focus that may reshape its development pipeline but underlines its broader commitment to expanding bioenergy capacity across multiple states.
The most recent analyst rating on (AU:DEL) stock is a Hold with a A$0.14 price target. To see the full list of analyst forecasts on Delorean Corporation Ltd stock, see the AU:DEL Stock Forecast page.